206 related articles for article (PubMed ID: 23377661)
21. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
[TBL] [Abstract][Full Text] [Related]
23. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).
Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Buhl-Jensen P; Molife R; Brown R; de Bono JS; Evans TR
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1273-9. PubMed ID: 20706839
[TBL] [Abstract][Full Text] [Related]
25. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Cho H; Yoon DH; Kim KP; Bae KS; Kim WS; Eom HS; Kim JS; Hong JY; Kim SJ; Lee H; Kim SJ; Suh C
Invest New Drugs; 2018 Oct; 36(5):877-885. PubMed ID: 29520651
[TBL] [Abstract][Full Text] [Related]
28. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
[TBL] [Abstract][Full Text] [Related]
29. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
Savelieva M; Woo MM; Schran H; Mu S; Nedelman J; Capdeville R
Eur J Clin Pharmacol; 2015 Jun; 71(6):663-672. PubMed ID: 25939707
[TBL] [Abstract][Full Text] [Related]
31. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
[TBL] [Abstract][Full Text] [Related]
32. Panobinostat: first global approval.
Garnock-Jones KP
Drugs; 2015 Apr; 75(6):695-704. PubMed ID: 25837990
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
35. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
36. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.
Chalret du Rieu Q; Fouliard S; White-Koning M; Kloos I; Chatelut E; Chenel M
Invest New Drugs; 2014 Oct; 32(5):985-94. PubMed ID: 24875134
[TBL] [Abstract][Full Text] [Related]
38. A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
Wood PJ; Strong R; McArthur GA; Michael M; Algar E; Muscat A; Rigby L; Ferguson M; Ashley DM
Cancer Chemother Pharmacol; 2018 Sep; 82(3):493-503. PubMed ID: 29987369
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
Strickler JH; Starodub AN; Jia J; Meadows KL; Nixon AB; Dellinger A; Morse MA; Uronis HE; Marcom PK; Zafar SY; Haley ST; Hurwitz HI
Cancer Chemother Pharmacol; 2012 Aug; 70(2):251-8. PubMed ID: 22744359
[TBL] [Abstract][Full Text] [Related]
40. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
Hamberg P; Woo MM; Chen LC; Verweij J; Porro MG; Zhao L; Li W; van der Biessen D; Sharma S; Hengelage T; de Jonge M
Cancer Chemother Pharmacol; 2011 Sep; 68(3):805-13. PubMed ID: 21706316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
